Despite FDA Regulation, 23andMe Continues Consumer-driven Research Focus to Grow Business | GenomeWeb

Originally published Aug. 19. Additional reporting by Molika Ashford.

NEW YORK (GenomeWeb) – While genomics firm 23andMe works with the US Food and Drug Administration to meet regulatory requirements for its roughly 200 health-related genetic test reports, the company's sustained focus on conducting consumer-driven research is enabling its continued growth.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.